The Straits TimesBusiness
iX Biopharma says US$41m Pentagon deal unaffected
iX Biopharma said a partner’s licence issue will not affect its forty-one-million-dollar ketamine wafer deal with the Pentagon. The company’s shares rose more than one percent on November fourth and have more than tripled this year.
This card is an AI-assisted summary of reporting published by The Straits Times. Read the original report before relying on it for medical, legal, financial, safety, or emergency decisions.